diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM7192diaendo-7192Research ArticleВопросы патогенезаPathogenesisМеханизмы нейропротективного действия инкретиномиметиковMechanisms of neuroprotective action of incretin mimeticsВласовТимур ДмитриевичVlasovTimur Dmitrievich

д.м.н., профессор, заведующий кафедрой патофизиологии с курсом клинической патофизиологии  Первого Санкт-Петербургского государственного медицинского университета им. акад. И.П. Павлова, ведущий научный сотрудник Института экспериментальной медицины СЗФМИЦ

MD, PhD, Professor

tvlasov@yandex.ruhttps://orcid.org/0000-0003-3300-1280СиманенковаАнна ВладимировнаSimanenkovaAnna Vladimirovna

клинический ординатор кафедры терапии факультетской с курсом эндокринологии, кардиологии и функциональной диагностики им. Г.Ф. Ланга Первого Санкт-Петербургского государственного медицинского университета им. акад. И.П. Павлова

MD, PhD-student

annasimanenkova@mail.ruДораСветлана ВладимировнаDoraSvetlana Vladimirovna

к.м.н, ассистент кафедры терапии факультетской с курсом эндокринологии, кардиологии и функциональной диагностики им. Г.Ф. Ланга Первого Санкт-Петербургского государственного медицинского университета им. акад. И.П. Павлова, старший научный сотрудник Института экспериментальной медицины СЗФМИЦ

MD

doras2001@mail.ruШляхтоЕвгений ВладимировичShlyakhtoEvgeniy Vladimirovich

д.м.н, профессор, академик РАН, заведующий кафедрой терапии  факультетской с курсом эндокринологии, кардиологии и функциональной диагностики им. Г.Ф. Ланга Первого Санкт-Петербургского государственного медицинского университета им. акад. И.П. Павлова, директор СЗФМИЦ

MD, PhD, Professor

eshlyakhto@spmu.rssi.ruГБОУ ВПО Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова; ФГБУ Северо-Западный федеральный медицинский исследовательский центрРоссияPavlov First Saint-Petersburg State medical University; Federal North-West Medical Research CenterRussian FederationГБОУ ВПО Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. ПавловаРоссияPavlov First Saint-Petersburg State medical University;Russian Federation2016150120161911623Copyright © Власов Т.Д., Симаненкова А.В., Дора С.В., Шляхто Е.В., 20162016Власов Т.Д., Симаненкова А.В., Дора С.В., Шляхто Е.В.Vlasov T.D., Simanenkova A.V., Dora S.V., Shlyakhto E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/7192

В последние годы на фармацевтическом рынке появились препараты из класса инкретиномиметиков, или агонистов рецептора глюкагоноподобного пептида-1 (ГПП-1), которые доказали свою высокую эффективность в терапии сахарного диабета 2 типа. В настоящее время большое внимание уделяется плейотропным эффектам инкретиномиметиков. В ряде работ, как экспериментальных, так и клинических, продемонстрирован кардиопротективный эффект данной группы препаратов. В настоящем обзоре освещаются имеющиеся данные о нейропротективном эффекте агонистов рецептора ГПП-1 при ишемии головного мозга и при неишемических заболеваниях нервной системы, таких как диабетическая нейропатия и нейродегенеративные заболевания. Кроме того, обсуждаются возможные механизмы реализации нейропротективного эффекта, основными из которых являются антиоксидантное и противовоспалительное действие, антиапоптотический эффект, усиление дифференцировки нейронов.

сахарный диабет 2 типаинкретиномиметикиагонисты рецептора глюкагоноподобного пептида-1нейропротекцияишемический инсультнейродегенеративные заболеванияtype 2 diabetes mellitusincretinomimeticsglucagon-like peptide-1 receptor agonistsneuroprotectionischemic strokeneurodegenerative diseasesРоссийский фонд фундаментальных исследований (грант № 14-04-32385/15)ReferencesIDF Diabetes Atlas. 6-th edition. 2013. Available from: http://www.idf.org/diabetesatlasIDF Diabetes Atlas. 6-th edition. 2013. Available from: http://www.idf.org/diabetesatlasКалашникова М.Ф., Сунцов Ю.И., Белоусов Д.Ю., и др. Анализ эпидемиологических показателей сахарного диабета 2 типа среди взрослого населения города Москвы. // Сахарный диабет. – 2014. – Т. 17. – №3 – С.5-16.[Kalashnikova MF, Suntsov YuI, Belousov DYu, et al. Analysis of epidemiological indices of type 2 diabetes mellitus in the adult population of Moscow. Diabetes mellitus. 2014;17(3):5-16. (In Russ).] doi: 10.14341/dm201435-16Калашникова М.Ф., Сунцов Ю.И., Белоусов Д.Ю., и др. Анализ эпидемиологических показателей сахарного диабета 2 типа среди взрослого населения города Москвы. // Сахарный диабет. – 2014. – Т. 17. – №3 – С.5-16.[Kalashnikova MF, Suntsov YuI, Belousov DYu, et al. Analysis of epidemiological indices of type 2 diabetes mellitus in the adult population of Moscow. Diabetes mellitus. 2014;17(3):5-16. (In Russ).] doi: 10.14341/dm201435-16Дедов И.И., Шестакова М.В. Инкретины: новая веха в лечении сахарного диабета 2-го типа. Практическое руководство для врачей. – М.: Дипак; 2010. [Dedov II, Shestakova MV. Inkretiny: novaya vekha v lechenii sakharnogo diabeta 2-go tipa. Prakticheskoe rukovodstvo dlya vrachei. Moscow: Dipak; 2010. (In Russ).]Дедов И.И., Шестакова М.В. Инкретины: новая веха в лечении сахарного диабета 2-го типа. Практическое руководство для врачей. – М.: Дипак; 2010. [Dedov II, Shestakova MV. Inkretiny: novaya vekha v lechenii sakharnogo diabeta 2-go tipa. Prakticheskoe rukovodstvo dlya vrachei. Moscow: Dipak; 2010. (In Russ).]Шестакова Е.А. Инкретиновая и «антиинкретиновая» системы в патогенезе сахарного диабета 2 типа: факты и гипотезы. // Сахарный диабет. – 2011. – Т. 14. – №3 – С.26-29. [Shestakova EA. New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems. Diabetes mellitus. 2011;14(3):26-29. (In Russ).] doi: 10.14341/2072-0351-6220Шестакова Е.А. Инкретиновая и «антиинкретиновая» системы в патогенезе сахарного диабета 2 типа: факты и гипотезы. // Сахарный диабет. – 2011. – Т. 14. – №3 – С.26-29. [Shestakova EA. New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems. Diabetes mellitus. 2011;14(3):26-29. (In Russ).] doi: 10.14341/2072-0351-6220Holst JJ. The physiology and pharmacology of incretins in type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. 2008;10:14-21. doi: 10.1111/j.1463-1326.2008.00920.xHolst JJ. The physiology and pharmacology of incretins in type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. 2008;10:14-21. doi: 10.1111/j.1463-1326.2008.00920.xАметов А.С., Бращенкова А.В. Роль и место инкретинов в достижении всестороннего гликемического контроля. // Русский медицинский журнал. – 2011. – Т. 19. – №27 — С.1690-1693. [Ametov AS, Brashchenkova AV. Rol’ i mesto inkretinov v dostizhenii vsestoronnego glikemicheskogo kontrolya. Russkii meditsinskii zhurnal. 2011;19(27):1690-1693. (In Russ).]Аметов А.С., Бращенкова А.В. Роль и место инкретинов в достижении всестороннего гликемического контроля. // Русский медицинский журнал. – 2011. – Т. 19. – №27 — С.1690-1693. [Ametov AS, Brashchenkova AV. Rol’ i mesto inkretinov v dostizhenii vsestoronnego glikemicheskogo kontrolya. Russkii meditsinskii zhurnal. 2011;19(27):1690-1693. (In Russ).]Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. The Journal of clinical endocrinology and metabolism. 2001;86(8):3717-3723. doi: 10.1210/jcem.86.8.7750Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. The Journal of clinical endocrinology and metabolism. 2001;86(8):3717-3723. doi: 10.1210/jcem.86.8.7750Li Y, Tweedie D, Mattson MP, et al. Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. Journal of neurochemistry. 2010;113(6):1621-1631. doi: 10.1111/j.1471-4159.2010.06731.xLi Y, Tweedie D, Mattson MP, et al. Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. Journal of neurochemistry. 2010;113(6):1621-1631. doi: 10.1111/j.1471-4159.2010.06731.xАнциферов М.Б., Дорофеева Л.Г. Новые подходы к лечению сахарного диабета типа 2: глюкагоноподобный пептид-1 и эксенатид (Баета). // Фарматека. – 2007. – №11 – С.14-19. [Antsiferov MB, Dorofeeva LG. Novye podkhody k lecheniyu sakharnogo diabeta tipa 2: glyukagonopodobnyi peptid-1 i eksenatid (Baeta). Farmateka. 2007;(11):14-19. (In Russ).]Анциферов М.Б., Дорофеева Л.Г. Новые подходы к лечению сахарного диабета типа 2: глюкагоноподобный пептид-1 и эксенатид (Баета). // Фарматека. – 2007. – №11 – С.14-19. [Antsiferov MB, Dorofeeva LG. Novye podkhody k lecheniyu sakharnogo diabeta tipa 2: glyukagonopodobnyi peptid-1 i eksenatid (Baeta). Farmateka. 2007;(11):14-19. (In Russ).]Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology. 2002;122(2):531-544. doi: 10.1053/gast.2002.31068Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology. 2002;122(2):531-544. doi: 10.1053/gast.2002.31068Schwasinger-Schmidt T, Robbins DC, Williams SJ, et al. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats. Pharmacological Research. 2013;76:58-66. doi: 10.1016/j.phrs.2013.07.005Schwasinger-Schmidt T, Robbins DC, Williams SJ, et al. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats. Pharmacological Research. 2013;76:58-66. doi: 10.1016/j.phrs.2013.07.005Wei Q, Sun YQ, Zhang J. Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits cell apoptosis induced by lipotoxicity in pancreatic β-cell line. Peptides. 2012;37(1):18-24. doi: 10.1016/j.peptides.2012.06.018Wei Q, Sun YQ, Zhang J. Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits cell apoptosis induced by lipotoxicity in pancreatic β-cell line. Peptides. 2012;37(1):18-24. doi: 10.1016/j.peptides.2012.06.018Bao W, Aravindhan K, Alsaid H, et al. Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency. PloS one. 2011;6(8):e23570. doi: 10.1371/journal.pone.0023570Bao W, Aravindhan K, Alsaid H, et al. Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency. PloS one. 2011;6(8):e23570. doi: 10.1371/journal.pone.0023570Dokken BB, La Bonte LR, Davis-Gorman G, et al. Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Hormone and metabolic research.2011;43(5):300-305. doi: 10.1055/s-0031-1271777Dokken BB, La Bonte LR, Davis-Gorman G, et al. Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Hormone and metabolic research.2011;43(5):300-305. doi: 10.1055/s-0031-1271777Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58(4):975-983. doi: 10.2337/db08-1193Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58(4):975-983. doi: 10.2337/db08-1193Liu Q, Anderson C, Broyde A, et al. Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovascular diabetology. 2010;9:76. doi: 10.1186/1475-2840-9-76Liu Q, Anderson C, Broyde A, et al. Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovascular diabetology. 2010;9:76. doi: 10.1186/1475-2840-9-76Lonborg J, Vejlstrup N, Kelbaek H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. European heart journal. 2012;33(12):1491-1499. doi: 10.1093/eurheartj/ehr309Lonborg J, Vejlstrup N, Kelbaek H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. European heart journal. 2012;33(12):1491-1499. doi: 10.1093/eurheartj/ehr309Read PA, Khan FZ, Dutka DP. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart. 2012;98(5):408-413. doi: 10.1136/hrt.2010.219345Read PA, Khan FZ, Dutka DP. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart. 2012;98(5):408-413. doi: 10.1136/hrt.2010.219345Nathanson D, Ullman B, Lofstrom U, et al. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia. 2012;55(4):926-935. doi: 10.1007/s00125-011-2440-xNathanson D, Ullman B, Lofstrom U, et al. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia. 2012;55(4):926-935. doi: 10.1007/s00125-011-2440-xBanerjee C, Moon YP, Paik MC, et al. Duration of diabetes and risk of ischemic stroke: the Northern Manhattan Study. Stroke. 2012;43(5):1212-1217. doi: 10.1161/STROKEAHA.111.641381Banerjee C, Moon YP, Paik MC, et al. Duration of diabetes and risk of ischemic stroke: the Northern Manhattan Study. Stroke. 2012;43(5):1212-1217. doi: 10.1161/STROKEAHA.111.641381Salcedo I, Tweedie D, Li Y, Greig NH. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. British journal of pharmacology. 2012;166(5):1586-1599. doi: 10.1111/j.1476-5381.2012.01971.xSalcedo I, Tweedie D, Li Y, Greig NH. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. British journal of pharmacology. 2012;166(5):1586-1599. doi: 10.1111/j.1476-5381.2012.01971.xBriyal S, Gulati K, Gulati A. Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats. Brain research. 2012;1427:23-34. doi: 10.1016/j.brainres.2011.10.026Briyal S, Gulati K, Gulati A. Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats. Brain research. 2012;1427:23-34. doi: 10.1016/j.brainres.2011.10.026Holst JJ, Burcelin R, Nathanson E. Neuroprotective properties of GLP-1: theoretical and practical applications. Current medical research and opinion. 2011;27(3):547-558. doi: 10.1185/03007995.2010.549466Holst JJ, Burcelin R, Nathanson E. Neuroprotective properties of GLP-1: theoretical and practical applications. Current medical research and opinion. 2011;27(3):547-558. doi: 10.1185/03007995.2010.549466Holscher C. Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. CNS drugs. 2012;26(10):871-882. doi: 10.2165/11635890-000000000-00000Holscher C. Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. CNS drugs. 2012;26(10):871-882. doi: 10.2165/11635890-000000000-00000Teramoto S, Miyamoto N, Yatomi K, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. Journal of cerebral blood flow and metabolism. 2011;31(8):1696-1705. doi: 10.1038/jcbfm.2011.51Teramoto S, Miyamoto N, Yatomi K, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. Journal of cerebral blood flow and metabolism. 2011;31(8):1696-1705. doi: 10.1038/jcbfm.2011.51Darsalia V, Mansouri S, Ortsater H, et al. Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats. Clinical science. 2012;122(10):473-483. doi: 10.1042/CS20110374Darsalia V, Mansouri S, Ortsater H, et al. Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats. Clinical science. 2012;122(10):473-483. doi: 10.1042/CS20110374Hara H, Huang PL, Panahian N, et al. Reduced brain edema and infarction volume in mice lacking the neuronal isoform of nitric oxide synthase after transient MCA occlusion. Journal of cerebral blood flow and metabolism. 1996;16(4):605-611. doi: 10.1097/00004647-199607000-00010Hara H, Huang PL, Panahian N, et al. Reduced brain edema and infarction volume in mice lacking the neuronal isoform of nitric oxide synthase after transient MCA occlusion. Journal of cerebral blood flow and metabolism. 1996;16(4):605-611. doi: 10.1097/00004647-199607000-00010Sato K, Kameda M, Yasuhara T, et al. Neuroprotective effects of liraglutide for stroke model of rats. International journal of molecular sciences. 2013;14(11):21513-21524. doi: 10.3390/ijms141121513Sato K, Kameda M, Yasuhara T, et al. Neuroprotective effects of liraglutide for stroke model of rats. International journal of molecular sciences. 2013;14(11):21513-21524. doi: 10.3390/ijms141121513Baba T, Kameda M, Yasuhara T, et al. Electrical stimulation of the cerebral cortex exerts antiapoptotic, angiogenic, and anti-inflammatory effects in ischemic stroke rats through phosphoinositide 3-kinase/Akt signaling pathway. Stroke. 2009;40(11):e598-605. doi: 10.1161/STROKEAHA.109.563627Baba T, Kameda M, Yasuhara T, et al. Electrical stimulation of the cerebral cortex exerts antiapoptotic, angiogenic, and anti-inflammatory effects in ischemic stroke rats through phosphoinositide 3-kinase/Akt signaling pathway. Stroke. 2009;40(11):e598-605. doi: 10.1161/STROKEAHA.109.563627Bederson JB, Pitts LH, Tsuji M, et al. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986;17(3):472-476. doi: 10.1161/01.str.17.3.472Bederson JB, Pitts LH, Tsuji M, et al. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986;17(3):472-476. doi: 10.1161/01.str.17.3.472Симаненкова А.В., Жигалова А.А., Шумеева А.Г., и др. Нейропротективное действие агониста рецептора глюкагоноподобного пептида-1 // Медицинский вестник Башкортостана. – 2014. – Т. 9. – №5 – С.156-159 [Simanenkova AV, Zhigalova AA, Shumeeva AG, et al. Neuroprotecrive effect of glucagon like peptide-1 receptor agonist. Meditsinskii vestnik Bashkortostana. 2014;9(5):156-159. (In Russ).]Симаненкова А.В., Жигалова А.А., Шумеева А.Г., и др. Нейропротективное действие агониста рецептора глюкагоноподобного пептида-1 // Медицинский вестник Башкортостана. – 2014. – Т. 9. – №5 – С.156-159 [Simanenkova AV, Zhigalova AA, Shumeeva AG, et al. Neuroprotecrive effect of glucagon like peptide-1 receptor agonist. Meditsinskii vestnik Bashkortostana. 2014;9(5):156-159. (In Russ).]Koizumi J, Yoshida Y, Nakazawa T, et al. Experimental studies of ischemic brain edema, I: a new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. Japanese Journal of Stroke. 1986;(8):1-8.Koizumi J, Yoshida Y, Nakazawa T, et al. Experimental studies of ischemic brain edema, I: a new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. Japanese Journal of Stroke. 1986;(8):1-8.Коржевский Д.Э., Кирик О.В., Байса А.Е., и др. Моделирование одностороннего ишемического повреждения нейронов стриатума с помощью непродолжительной окклюзии средней мозговой артерии // Бюллетень экспериментальной биологии и медицины. – 2009. – Т. 147. – №2 – С.217-219. [Korzhevskii DE, Kirik OV, Baisa AE, et al. Simulation of unilateral ischemic injury to the striatal neurons inflicted by short-term occlusion of the middle cerebral artery. Bulletin of experimental biology and medicine. 2009;147(2):217-219. (In Russ).] doi: 10.1007/s10517-009-0487-1Коржевский Д.Э., Кирик О.В., Байса А.Е., и др. Моделирование одностороннего ишемического повреждения нейронов стриатума с помощью непродолжительной окклюзии средней мозговой артерии // Бюллетень экспериментальной биологии и медицины. – 2009. – Т. 147. – №2 – С.217-219. [Korzhevskii DE, Kirik OV, Baisa AE, et al. Simulation of unilateral ischemic injury to the striatal neurons inflicted by short-term occlusion of the middle cerebral artery. Bulletin of experimental biology and medicine. 2009;147(2):217-219. (In Russ).] doi: 10.1007/s10517-009-0487-1Коржевский Д.Э., Кирик О.В., Сухорукова Е.Г., и др. Структурная организация микроглиоцитов стриатума после транзиторной фокальной ишемии // Морфология. – 2012. – Т. 141. – №2 – С.28-32. [Korzhevskii DE, Kirik OV, Sukhorukova YeG, et al. Structural organization of striatal microgliocytes following focal ischemia. Morfologiya. 2012;141(2):28-32. (In Russ).]Коржевский Д.Э., Кирик О.В., Сухорукова Е.Г., и др. Структурная организация микроглиоцитов стриатума после транзиторной фокальной ишемии // Морфология. – 2012. – Т. 141. – №2 – С.28-32. [Korzhevskii DE, Kirik OV, Sukhorukova YeG, et al. Structural organization of striatal microgliocytes following focal ischemia. Morfologiya. 2012;141(2):28-32. (In Russ).]Garcia GH, Wagner S, Liu KF, et al. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats: statistical validation. Stroke. 1995;26(4):627-634. doi: 10.1161/01.str.26.4.627Garcia GH, Wagner S, Liu KF, et al. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats: statistical validation. Stroke. 1995;26(4):627-634. doi: 10.1161/01.str.26.4.627Warner DS, Sheng H, Batinic-Haberle I. Oxidants, antioxidants and the ischemic brain. The Journal of experimental biology. 2004;207(Pt 18):3221-3231. doi: 10.1242/jeb.01022Warner DS, Sheng H, Batinic-Haberle I. Oxidants, antioxidants and the ischemic brain. The Journal of experimental biology. 2004;207(Pt 18):3221-3231. doi: 10.1242/jeb.01022Love S. Oxidative Stress in Brain Ischemia. Brain Pathology. 1999;9(1):119-131. doi: 10.1111/j.1750-3639.1999.tb00214.xLove S. Oxidative Stress in Brain Ischemia. Brain Pathology. 1999;9(1):119-131. doi: 10.1111/j.1750-3639.1999.tb00214.xAndrabi SA, Sayeed I, Siemen D, et al. Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti-apoptotic effects of melatonin. FASEB journal. 2004;18(7):869-871. doi: 10.1096/fj.03-1031fjeAndrabi SA, Sayeed I, Siemen D, et al. Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti-apoptotic effects of melatonin. FASEB journal. 2004;18(7):869-871. doi: 10.1096/fj.03-1031fjePerry T, Haughey NJ, Mattson MP, et al. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. The Journal of pharmacology and experimental therapeutics. 2002;302(3):881-888. doi: 10.1124/jpet.102.037481Perry T, Haughey NJ, Mattson MP, et al. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. The Journal of pharmacology and experimental therapeutics. 2002;302(3):881-888. doi: 10.1124/jpet.102.037481Perry T, Lahiri DK, Chen D, et al. A Novel Neurotrophic Property of Glucagon-Like Peptide 1: A Promoter of Nerve Growth Factor-Mediated Differentiation in PC12 Cells. Journal of Pharmacology and Experimental Therapeutics. 2002;300(3):958-966. doi: 10.1124/jpet.300.3.958Perry T, Lahiri DK, Chen D, et al. A Novel Neurotrophic Property of Glucagon-Like Peptide 1: A Promoter of Nerve Growth Factor-Mediated Differentiation in PC12 Cells. Journal of Pharmacology and Experimental Therapeutics. 2002;300(3):958-966. doi: 10.1124/jpet.300.3.958Perry T, Lahiri DK, Sambamurti K, et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. Journal of neuroscience research. 2003;72(5):603-612. doi: 10.1002/jnr.10611Perry T, Lahiri DK, Sambamurti K, et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. Journal of neuroscience research. 2003;72(5):603-612. doi: 10.1002/jnr.10611Yamada S, Funada T, Shibata N, et al. Protein-bound 4-hydroxy-2-hexenal as a marker of oxidized n-3 polyunsaturated fatty acids. Journal of lipid research. 2004;45(4):626-634. doi: 10.1194/jlr.M300376-JLR200Yamada S, Funada T, Shibata N, et al. Protein-bound 4-hydroxy-2-hexenal as a marker of oxidized n-3 polyunsaturated fatty acids. Journal of lipid research. 2004;45(4):626-634. doi: 10.1194/jlr.M300376-JLR200Kitagawa K. CREB and cAMP response element-mediated gene expression in the ischemic brain. The FEBS journal. 2007;274(13):3210-3217. doi: 10.1111/j.1742-4658.2007.05890.xKitagawa K. CREB and cAMP response element-mediated gene expression in the ischemic brain. The FEBS journal. 2007;274(13):3210-3217. doi: 10.1111/j.1742-4658.2007.05890.xYin F, Liu JH, Zheng XX, Guo LX. GLP-1 receptor plays a critical role in geniposide-induced expression of heme oxygenase-1 in PC12 cells. Acta Pharmacol Sin. 2010;31(5):540-545. doi: 10.1038/aps.2010.28Yin F, Liu JH, Zheng XX, Guo LX. GLP-1 receptor plays a critical role in geniposide-induced expression of heme oxygenase-1 in PC12 cells. Acta Pharmacol Sin. 2010;31(5):540-545. doi: 10.1038/aps.2010.28Stocker R, Yamamoto Y, McDonagh AF, et al. Bilirubin is an antioxidant of possible physiological importance. Science. 1987;235(4792):1043-1046. doi: 10.1126/science.3029864Stocker R, Yamamoto Y, McDonagh AF, et al. Bilirubin is an antioxidant of possible physiological importance. Science. 1987;235(4792):1043-1046. doi: 10.1126/science.3029864Ferris CD, Jaffrey SR, Sawa A, et al. Haem oxygenase-1 prevents cell death by regulating cellular iron. Nature cell biology. 1999;1(3):152-157. doi: 10.1038/11072Ferris CD, Jaffrey SR, Sawa A, et al. Haem oxygenase-1 prevents cell death by regulating cellular iron. Nature cell biology. 1999;1(3):152-157. doi: 10.1038/11072Park SH, Jang JH, Li MH, et al. Nrf2-mediated heme oxygenase-1 induction confers adaptive survival response to tetrahydropapaveroline-induced oxidative PC12 cell death. Antioxidants & redox signaling. 2007;9(12):2075-2086. doi: 10.1089/ars.2007.1828Park SH, Jang JH, Li MH, et al. Nrf2-mediated heme oxygenase-1 induction confers adaptive survival response to tetrahydropapaveroline-induced oxidative PC12 cell death. Antioxidants & redox signaling. 2007;9(12):2075-2086. doi: 10.1089/ars.2007.1828Surh YJ, Kundu JK, Li MH, et al. Role of Nrf2-mediated heme oxygenase-1 upregulation in adaptive survival response to nitrosative stress. Archives of pharmacal research. 2009;32(8):1163-1176. doi: 10.1007/s12272-009-1807-8Surh YJ, Kundu JK, Li MH, et al. Role of Nrf2-mediated heme oxygenase-1 upregulation in adaptive survival response to nitrosative stress. Archives of pharmacal research. 2009;32(8):1163-1176. doi: 10.1007/s12272-009-1807-8Liu JH, Yin F, Guo LX, et al. Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: involvement of PI3 kinase signal pathway. Acta Pharmacol Sin. 2009;30(2):159-165. doi: 10.1038/aps.2008.25Liu JH, Yin F, Guo LX, et al. Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: involvement of PI3 kinase signal pathway. Acta Pharmacol Sin. 2009;30(2):159-165. doi: 10.1038/aps.2008.25Liu WJ, Jin HY, Lee KA, et al. Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats. British journal of pharmacology. 2011;164(5):1410-1420. doi: 10.1111/j.1476-5381.2011.01272.xLiu WJ, Jin HY, Lee KA, et al. Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats. British journal of pharmacology. 2011;164(5):1410-1420. doi: 10.1111/j.1476-5381.2011.01272.xHamilton A, Patterson S, Porter D, et al. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. Journal of neuroscience research. 2011;89(4):481-489. doi: 10.1002/jnr.22565Hamilton A, Patterson S, Porter D, et al. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. Journal of neuroscience research. 2011;89(4):481-489. doi: 10.1002/jnr.22565Салмина А.Б., Яузина Н.А., Кувачева Н.В., и др. Инсулин и инсулинорезистентность: новые молекулы-маркеры и молекулы-мишени для диагностики и терапии заболеваний центральной нервной системы // Бюллетень сибирской медицины. – 2013. – Т. 12. – №5 – С. 104-118. [Salmina AB, Yauzina NA, Kuvacheva NV, et al. Insulin and insulin resistance: new molecule markers and target molecule for the diagnosis and therapy of diseases of the central nervous system. Bulletin of Siberian Medicine. 2013;12(5):104–118. (In Russ).]Салмина А.Б., Яузина Н.А., Кувачева Н.В., и др. Инсулин и инсулинорезистентность: новые молекулы-маркеры и молекулы-мишени для диагностики и терапии заболеваний центральной нервной системы // Бюллетень сибирской медицины. – 2013. – Т. 12. – №5 – С. 104-118. [Salmina AB, Yauzina NA, Kuvacheva NV, et al. Insulin and insulin resistance: new molecule markers and target molecule for the diagnosis and therapy of diseases of the central nervous system. Bulletin of Siberian Medicine. 2013;12(5):104–118. (In Russ).]Shah K, Desilva S, Abbruscato T. The role of glucose transporters in brain disease: diabetes and Alzheimer’s Disease. International journal of molecular sciences. 2012;13(10):12629-12655. doi: 10.3390/ijms131012629Shah K, Desilva S, Abbruscato T. The role of glucose transporters in brain disease: diabetes and Alzheimer’s Disease. International journal of molecular sciences. 2012;13(10):12629-12655. doi: 10.3390/ijms131012629Harkavyi A, Whitton PS. Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. British journal of pharmacology. 2010;159(3):495-501. doi: 10.1111/j.1476-5381.2009.00486.xHarkavyi A, Whitton PS. Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. British journal of pharmacology. 2010;159(3):495-501. doi: 10.1111/j.1476-5381.2009.00486.xMalhotra JD, Kaufman RJ. Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword? Antioxidants & redox signaling. 2007;9(12):2277-2293. doi: 10.1089/ars.2007.1782Malhotra JD, Kaufman RJ. Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword? Antioxidants & redox signaling. 2007;9(12):2277-2293. doi: 10.1089/ars.2007.1782Yusta B, Baggio LL, Estall JL, et al. GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab. 2006;4(5):391-406. doi: 10.1016/j.cmet.2006.10.001Yusta B, Baggio LL, Estall JL, et al. GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab. 2006;4(5):391-406. doi: 10.1016/j.cmet.2006.10.001Harding HP, Zhang Y, Bertolotti A, et al. Perk Is Essential for Translational Regulation and Cell Survival during the Unfolded Protein Response. Molecular Cell. 2000;5(5):897-904. doi: 10.1016/S1097-2765(00)80330-5Harding HP, Zhang Y, Bertolotti A, et al. Perk Is Essential for Translational Regulation and Cell Survival during the Unfolded Protein Response. Molecular Cell. 2000;5(5):897-904. doi: 10.1016/S1097-2765(00)80330-5Hou J, Manaenko A, Hakon J, et al. Liraglutide, a long-acting GLP-1 mimetic, and its metabolite attenuate inflammation after intracerebral hemorrhage. Journal of cerebral blood flow and metabolism. 2012;32(12):2201-2210. doi: 10.1038/jcbfm.2012.133Hou J, Manaenko A, Hakon J, et al. Liraglutide, a long-acting GLP-1 mimetic, and its metabolite attenuate inflammation after intracerebral hemorrhage. Journal of cerebral blood flow and metabolism. 2012;32(12):2201-2210. doi: 10.1038/jcbfm.2012.133

The authors declare that there are no conflicts of interest present.